| Project/Area Number |
16K18445
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Tumor diagnostics
|
|---|
| Research Institution | Japanese Foundation for Cancer Research |
|---|
Principal Investigator |
Udagawa Chihiro 公益財団法人がん研究会, がんプレシジョン医療研究センター, 客員研究員 (20774160)
|
|---|
| Research Collaborator |
ZEMBUTSU Hitoshi 公益財団法人がん研究会, がんプレシジョン医療研究センター リキッドバイオプシー診断開発プロジェクト, プロジェクトリーダー (90372820)
|
|---|
| Project Period (FY) |
2016-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2017: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2016: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
|---|
| Keywords | pharmacogenomics / xenograft / 抗がん剤 / precision medicine / バイオマーカー / 癌 / PGx |
|---|
| Outline of Final Research Achievements |
In the current study, to identify genetic markers for sensitivity or resistance to 9 cytotoxic anticancer drugs, all exons of 409 genes associated with cancer from 79 cancer xenografts in mice that had been established from 12 different human organs were sequenced. The association between single nucleotide variants (SNVs) detected in the xenografts and sensitivities to the 9 cytotoxic anticancer drugs were then investigated using a nonparametric approach. We identified 35 SNVs associated with sensitivities to one or more of the nine anticancer drugs. These findings provide novel insights which may benefit the development of personalized anticancer therapy for patients with cancer in the future.
|
